GlassScriptPhysician profile
Susan Meram
NPI 1588630735
$4,656.27
in general payments reported to CMS, 2019-2025
33 companies · $853 in 2025
The $853 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $460 · 2021: $570 · 2022: $573 · 2023: $727 · 2024: $830 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $749.95 | 2019-2024 | Farxiga, Airsupra, Evusheld |
| Lilly USA, LLC | $742.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $739.57 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $316.91 | 2021-2023 | |
| Amgen INC. | $279.35 | 2019-2025 | Repatha, Otezla, Evenity |
| Biohaven Pharmaceutical Holding Company LTD. | $251.48 | 2022 | |
| Pfizer INC. | $183.53 | 2023-2025 | |
| Glaxosmithkline, LLC. | $155.29 | 2019-2025 | Shingrix, Arexvy |
| Eisai INC. | $131.03 | 2024 | |
| Axsome Therapeutics, INC. | $126.33 | 2023-2024 | Auvelity, Sunosi |
| Heartflow, INC. | $121.76 | 2025 | |
| Novartis Pharmaceuticals Corporation | $114.46 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $114.28 | 2022-2025 | |
| Nevro Corp. | $67.95 | 2022 | |
| Inspire Medical Systems, INC. | $54.60 | 2024 | Inspire |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $50.47 | 2019-2023 | Auvi-Q |
| Intra-Sana Laboratories | $50.00 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Takeda Pharmaceuticals U.S.A., INC. | $48.44 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $33.76 | 2019 | |
| Therapeuticsmd, INC. | $33.10 | 2019-2022 | |
| Abbott Laboratories | $31.59 | 2020 | |
| Ibsa Pharma INC. | $30.82 | 2025 | Tirosint, Licart, Flector |
| Allergan, INC. | $30.11 | 2020 | |
| Merck Sharp & Dohme LLC | $26.28 | 2025 | Enflonsia, Capvaxive, Gardasil 9 |
| Mayne Pharma Commercial LLC | $24.65 | 2023 | |
| Jazz Pharmaceuticals INC. | $22.44 | 2021 | |
| Sumitomo Pharma America, INC. | $21.40 | 2025 | Gemtesa |
| Phadia US INC. | $19.73 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.57 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.60 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.21 | 2025 | |
| Astellas Pharma US INC | $16.43 | 2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Meram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.